Next-Generation TYK2 Inhibitors for Psoriasis Treatment
According to Benjamin Lockshin, M.D., from Georgetown University, oral TYK2 inhibitors have revolutionized the management of patients with psoriasis, offering efficacy comparable to biologics.
The approval of Sotyktu (deucravacitinib) in 2022 marked a significant milestone in psoriasis treatment, as it was the first oral medication to inhibit tyrosine kinase 2 (TYK2), an enzyme involved in inflammatory and immune responses.
- Developed by Bristol Myers Squibb, Sotyktu is used to treat moderate-to-severe plaque psoriasis.
- It remains the only medication in its class.
Psoriasis is a chronic, systemic, immune-mediated disease affecting approximately 7.5 million people in the United States, with nearly one-quarter of cases considered moderate-to-severe.
No direct quotes available in the provided text.
Author's summary: Next-gen TYK2 inhibitors show promise.
More News
- Shreya Sen-Handley | Ditch That Smartphone, Get Out, Get A W/Life
- 15 Years Later: Revisiting Star Wars: The Force Unleashed II
- ‘Chainsaw Man’ Whips Past $100M WW; ‘One Battle After Another’ Keeps Raging – International Box Office
- CFMEU administrator sent corruption-busters away, then had to sack top figure
- Jacksonville-based tech innovator ParkerVision stifled by Chinese interference, judicial abuse
- After more than a decade, Paul McCartney finally got back to San Antonio — and maybe we're amazed
- Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
- Somber Start, Triumphant Finish: Furusato Claims Maiden Victory Amid Difficult Day in Sepang
- CFMEU administrator sent corruption-busters away, then had to sack top figure
- South Carolina upset of Alabama falls short